Track market-moving stories before they get noisy

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire

NEW YORK, Sept. 2, 2026

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Geron Corporation (NASDAQ: GERN) breached their fiduciary duties to shareholders.

If you currently own Geron stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/did-geron-corporation-insiders-breach-their-fiduciary-duties-to-shareholders-302868041.html

SOURCE Halper Sadeh LLP

CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs. Insider Cluster Buys: Stocks that multiple company officers and directors have bought. Double Buys: Companies that both Gurus and Insiders are buying Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.

, /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Geron Corporation (NASDAQ: GERN) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Geron Corporation misrepresented or failed to disclose the true state of its sole commercial product, Rytelo, including that: (1) Rytelo's commercial launch was plagued by open conflict between the Company's medical and commercial teams; (2) the Company's sales force was sent into the market without any marketing materials beyond the bare FDA prescribing information; (3) the Company had failed to educate its primary target market – community physicians – about Rytelo; and (4) that as a result, Rytelo's growth and revenue had flattened only weeks after its launch.

If you currently own GERN and purchased prior to February 28, 2024 please contact Sophia Anne Silayan by email at [email protected] or call (833) 672-0814.  Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814

SOURCE Kuehn Law, PLLC

ADAR1 Capital Management LLC purchased a new stake in Geron Corporation (NASDAQ:GERN – Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 505,817 shares of the biopharmaceutical company’s stock, valued at approximately $647,000. ADAR1 Capital Management LLC owned approximately 0.08% of Geron at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Hsbc Holdings PLC acquired a new stake in Geron in the second quarter valued at approximately $25,000. Canada Pension Plan Investment Board purchased a new position in shares of Geron in the second quarter valued at $115,000. Legal & General Group Plc purchased a new position in shares of Geron in the second quarter valued at $396,000. The Manufacturers Life Insurance Company acquired a new stake in Geron during the 2nd quarter valued at $191,000. Finally, Forefront Analytics LLC acquired a new stake in Geron during the 2nd quarter valued at $114,000. 73.71% of the stock is owned by hedge funds and other institutional investors.

Geron Trading Up 2.0% Shares of GERN stock opened at $1.55 on Wednesday. The stock has a 50-day simple moving average of $1.43 and a 200 day simple moving average of $1.48. The stock has a market capitalization of $995.83 million, a P/E ratio of -14.09 and a beta of 0.61. Geron Corporation has a fifty-two week low of $1.04 and a fifty-two week high of $2.01. The company has a quick ratio of 5.16, a current ratio of 6.91 and a debt-to-equity ratio of 0.55.

Geron (NASDAQ:GERN – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01). The business had revenue of $57.48 million during the quarter, compared to analyst estimates of $55.30 million. Geron had a negative return on equity of 24.48% and a negative net margin of 34.17%. On average, sell-side analysts expect that Geron Corporation will post -0.04 earnings per share for the current fiscal year. Wall Street Analysts Forecast Growth Separately, Weiss Ratings raised Geron from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Geron currently has a consensus rating of “Hold” and a consensus target price of $4.00.

Get Our Latest Analysis on Geron

About Geron (Free Report)

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.

See Also Five stocks we like better than Geron Pathward’s Credit Scare Tests Its Comeback Story Wiring the AI Boom: Rumble’s $13.7B Pivot StoneX: Too Far Too Fast? DICK’s Sporting Goods Faces Pain Now for a Bigger Prize

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.

9.27K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of GERN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Geron (GERN - Free Report) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -100.00%. A quarter ago, it was expected that this drugmaker would post a loss of $0.03 per share when it actually produced a loss of $0.01, delivering a surprise of +66.67%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

Geron, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $57.48 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 4.49%. This compares to year-ago revenues of $49.04 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Geron shares have added about 1.5% since the beginning of the year versus the S&P 500's gain of 13%.

What's Next for Geron?While Geron has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Geron was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.01 on $58.52 million in revenues for the coming quarter and -$0.02 on $231.15 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Editas Medicine (EDIT - Free Report) , is yet to report results for the quarter ended June 2026.

This genome editing company is expected to post quarterly loss of $0.30 per share in its upcoming report, which represents a year-over-year change of +52.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Editas Medicine's revenues are expected to be $1.9 million, down 46.8% from the year-ago quarter.

Geron Corporation: FDA Approval Fuels Stock Price SurgeGeron NASDAQ: GERN reported second-quarter net revenue of $57.5 million, up 17% from a year earlier and 11% sequentially, as the company continued to expand use of RYTELO among patients with lower-risk myelodysplastic syndromes, or MDS.

Chief Executive Officer Harout Semerjian said first-half net revenue rose approximately 24% from the same period in 2025, while total operating expenses declined 4%. The company ended the quarter with $327 million in cash, cash equivalents, restricted cash and marketable securities.

Get Geron alerts:

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval “We delivered another quarter of net revenue growth, expanding RYTELO's reach to more eligible patients,” Semerjian said. “We delivered another quarter of net revenue growth, expanding RYTELO's reach to more eligible patients, strengthened the clinical evidence supporting RYTELO, continued investing in future growth opportunities, all while remaining financially disciplined.”

RYTELO Demand and Commercial Execution Geron said RYTELO demand increased 5% in the second quarter compared with the first quarter, marking its third consecutive quarter of demand growth. The number of prescribing accounts increased 8% to approximately 1,575 since the product's launch.

Ahmed ElNawawi, Geron’s chief commercial officer, said patient starts in the first- and second-line settings represented 34% on a rolling 12-month basis. The company is prioritizing high-volume community treatment centers, earlier identification of eligible patients, account management and targeted engagement with health-care professionals.

Geron estimates that approximately 8,000 patients in the United States may be eligible for RYTELO in the second-line, lower-risk MDS setting.

During the question-and-answer session, Semerjian said sales growth is coming from both new and existing prescribing accounts. ElNawawi added that the company expects expansion into new accounts, or breadth, to become a smaller contributor during the second half, while greater use within existing accounts, or depth, becomes a more important metric.

ElNawawi said Geron does not currently have a reliable metric for measuring duration of therapy and therefore cannot determine whether persistence is increasing or decreasing.

Guidance Points to Higher End of Revenue Range Based on first-half performance, Geron expects 2026 RYTELO net product revenue to land at the mid-to-high end of its previously stated $220 million to $240 million guidance range. The company continues to expect total operating expenses of $230 million to $240 million for the year.

Chief Financial Officer Michelle Robertson said the company expects consistent quarter-over-quarter revenue growth through the remainder of 2026. Geron manages inventory within a two- to four-week range and does not expect significant inventory-related increases or decreases in the second half, she said.

Second-quarter gross-to-net deductions rose to 20.7%, compared with 15.3% in the year-earlier period. Geron continues to expect gross-to-net deductions in the low-to-mid-20% range for the remainder of the year.

Research and development expense was $22 million, compared with $21.7 million a year earlier. Selling, general and administrative expense was $38.9 million, compared with $38.6 million in the prior-year quarter. Total operating expenses, excluding cost of goods sold, were $60.7 million, compared with $60.3 million a year earlier. Robertson attributed higher research and development spending to investments in chemistry, manufacturing and controls, or CMC, and said higher marketing expenses affected selling, general and administrative costs. These increases were partially offset by lower personnel costs following the company’s workforce reduction in December 2025.

Real-World Evidence and Myelofibrosis Program At the European Hematology Association congress, Geron presented retrospective results from an investigator-sponsored real-world study conducted with Moffitt Cancer Center. The two-part retrospective and prospective study is evaluating RYTELO’s safety and clinical efficacy in advanced, heavily transfusion-dependent lower-risk MDS patients, including patients with extensive prior therapies and prior luspatercept failure.

Semerjian said the retrospective findings were generally consistent with the Phase III IMerge trial and supported RYTELO’s safety, efficacy and tolerability profile in a broader patient population. The data also indicated a trend toward better management of cytopenias and improved responses when RYTELO was used in the first three lines of therapy.

Chief Medical Officer Joseph Eid said the company expects to present insights from the prospective portion of the study at a future scientific meeting.

Geron also discussed its Phase III IMpactMF trial of imetelstat in relapsed or refractory myelofibrosis. The company has engaged regulators and outside experts regarding the design of the trial’s interim analysis and is evaluating a modification to the event threshold that would support registration if the data monitoring committee recommends unblinding for positive efficacy.

Eid said the potential modification concerns the interim analysis and would not change the final overall-survival analysis, which remains the trial’s primary endpoint. Geron’s base-case expectation remains for the final overall-survival analysis in the second half of 2028, while a positive result at the interim analysis would be an earlier upside scenario.

European Commercial Plans Expected Before Year-End Geron said it is exploring a “gated” commercialization strategy for RYTELO in Europe and other markets while seeking to preserve U.S. pricing integrity. The company expects to provide an update on its European commercialization plans before the end of 2026.

Semerjian said Geron sees a patient opportunity in Europe comparable in scale to the U.S. market and is engaging medical experts and payers. He said the company is monitoring evolving most-favored-nation dynamics and expects to assess potential approaches in major markets including Germany and France. Potential strategies could include partnership arrangements, he said.

Geron also announced that Chinmaya Rath joined the company as chief business officer. Semerjian said Rath’s appointment supports the company’s effort to identify strategic growth opportunities and build Geron into a leading hematology company.

About Geron (NASDAQ:GERN)Geron Corporation NASDAQ: GERN is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company's research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Geron Right Now?Before you consider Geron, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.

While Geron currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Posted by Defense World Staff on Aug 4th, 2026

Geron (NASDAQ:GERN – Get Free Report) is projected to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $55.3030 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

Geron (NASDAQ:GERN – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. Geron had a negative net margin of 35.48% and a negative return on equity of 23.31%. The business had revenue of $51.84 million for the quarter, compared to the consensus estimate of $50.59 million. On average, analysts expect Geron to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Geron Stock Down 0.8% GERN stock opened at $1.28 on Tuesday. The firm has a market cap of $821.15 million, a PE ratio of -11.64 and a beta of 0.60. Geron has a 1 year low of $1.04 and a 1 year high of $2.01. The company has a fifty day simple moving average of $1.32 and a 200 day simple moving average of $1.46. The company has a current ratio of 6.78, a quick ratio of 4.96 and a debt-to-equity ratio of 0.52.

Analyst Ratings Changes Separately, Weiss Ratings lowered Geron from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 24th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Geron currently has a consensus rating of “Hold” and an average target price of $4.00.

Check Out Our Latest Stock Report on GERN

Institutional Trading of Geron A number of institutional investors and hedge funds have recently modified their holdings of GERN. Virtu Financial LLC bought a new stake in shares of Geron during the 4th quarter worth $171,000. Invesco Ltd. raised its holdings in Geron by 27.6% in the 4th quarter. Invesco Ltd. now owns 1,225,658 shares of the biopharmaceutical company’s stock worth $1,618,000 after acquiring an additional 265,197 shares during the period. Mercer Global Advisors Inc. ADV raised its holdings in Geron by 104.4% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 91,619 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 46,801 shares during the period. XTX Topco Ltd lifted its position in Geron by 56.1% during the 4th quarter. XTX Topco Ltd now owns 258,397 shares of the biopharmaceutical company’s stock worth $341,000 after acquiring an additional 92,881 shares during the last quarter. Finally, Virtus Investment Advisers LLC boosted its holdings in Geron by 76.4% during the fourth quarter. Virtus Investment Advisers LLC now owns 502,509 shares of the biopharmaceutical company’s stock valued at $663,000 after acquiring an additional 217,641 shares during the period. 73.71% of the stock is currently owned by institutional investors and hedge funds.

Geron Company Profile (Get Free Report)

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.

Recommended Stories Five stocks we like better than Geron SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control Why Rare Earth Processing Could Be the Real 2027 Opportunity The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECalifornia State Teachers Retirement System Purchases 9,179 Shares of Ryder System, Inc. $R

NEXT HEADLINE »California State Teachers Retirement System Raises Position in CubeSmart $CUBE

July 22, 2026 07:00 ET  | Source: Geron Corporation

FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026, via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.

A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company’s website at www.geron.com.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]

July 14, 2026 16:26 ET  | Source: Geron Corporation

FOSTER CITY, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 1,700,000 shares of Geron common stock to Chinmaya Rath, Geron’s new Chief Business Officer, as an inducement material to his acceptance of employment with Geron.

The stock option was granted on July 13, 2026. The stock option has an exercise price of $1.42 per share, which is equal to the closing price of Geron’s common stock on the grant date, has a ten-year term and vests over four years, with 12.5% of the shares underlying the option vesting on the six-month anniversary of commencement of his employment and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued service with Geron through the applicable vesting dates.

The stock option grant was approved by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and is subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under that plan.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]

Geron Corporation delivered Q1'26 Rytelo revenues of $51.8M, up 8% sequentially, with two consecutive quarters of demand growth. GERN maintained 2026 guidance, with net product revenues of $220M-$240M expected. Management is now prioritizing high-volume community accounts, aiming to shift sales mix from academic centers to the broader 80% community-driven market.

Posted by Defense World Staff on Mar 31st, 2026

Geron Corporation (NASDAQ:GERN – Get Free Report)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.38 and traded as high as $1.43. Geron shares last traded at $1.41, with a volume of 16,679,509 shares.

Analyst Ratings Changes Several brokerages recently issued reports on GERN. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Geron in a research report on Wednesday, January 28th. HC Wainwright reissued a “neutral” rating on shares of Geron in a research report on Tuesday, December 9th. UBS Group restated a “neutral” rating on shares of Geron in a research note on Tuesday, December 9th. Finally, TD Cowen reiterated a “buy” rating on shares of Geron in a research note on Thursday, January 29th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Geron has an average rating of “Hold” and a consensus target price of $2.17.

Check Out Our Latest Stock Analysis on GERN

Geron Stock Performance The company’s 50-day simple moving average is $1.56 and its 200 day simple moving average is $1.38. The company has a current ratio of 4.66, a quick ratio of 3.62 and a debt-to-equity ratio of 0.53. The stock has a market cap of $903.16 million, a P/E ratio of -10.85 and a beta of 0.58.

Geron (NASDAQ:GERN – Get Free Report) last released its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.02). The business had revenue of $48.02 million during the quarter, compared to the consensus estimate of $50.43 million. Geron had a negative net margin of 46.65% and a negative return on equity of 28.86%. As a group, sell-side analysts expect that Geron Corporation will post -0.25 EPS for the current fiscal year.

Institutional Inflows and Outflows A number of institutional investors have recently bought and sold shares of the business. RA Capital Management L.P. raised its stake in shares of Geron by 5.6% during the 4th quarter. RA Capital Management L.P. now owns 63,771,366 shares of the biopharmaceutical company’s stock worth $84,178,000 after purchasing an additional 3,392,000 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Geron by 3.6% in the 4th quarter. Vanguard Group Inc. now owns 35,660,969 shares of the biopharmaceutical company’s stock worth $47,072,000 after buying an additional 1,237,844 shares during the last quarter. State Street Corp grew its position in Geron by 0.9% during the fourth quarter. State Street Corp now owns 26,867,322 shares of the biopharmaceutical company’s stock valued at $35,465,000 after buying an additional 248,508 shares during the period. Vestal Point Capital LP grew its position in Geron by 8.0% during the second quarter. Vestal Point Capital LP now owns 23,775,000 shares of the biopharmaceutical company’s stock valued at $33,523,000 after buying an additional 1,769,660 shares during the period. Finally, Eversept Partners LP increased its holdings in Geron by 40.2% during the fourth quarter. Eversept Partners LP now owns 17,659,983 shares of the biopharmaceutical company’s stock worth $23,311,000 after buying an additional 5,060,981 shares during the last quarter. Institutional investors own 73.71% of the company’s stock.

About Geron (Get Free Report)

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.

Featured Articles Five stocks we like better than Geron Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEOmeros (NASDAQ:OMER) Share Price Passes Above 200 Day Moving Average – Here’s Why

NEXT HEADLINE »Strattec Security (NASDAQ:STRT) Share Price Crosses Above 200-Day Moving Average – Should You Sell?

Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies

Geron (NASDAQ:GERN) executives used a presentation at the Needham Healthcare Conference to outline the company’s early commercial trajectory for its telomerase inhibitor imetelstat (marketed as RYTELO) in lower-risk myelodysplastic syndromes (MDS), provide updated views on physician adoption dynamics, and discuss the ongoing Phase 3 myelofibrosis (MF) program.

Commercial launch status and financial outlook President and CEO Harout Semerjian described Geron as a “commercial-stage company focused in hematology-oncology,” noting that the company launched “the first telomerase inhibitor, imetelstat,” in the middle of 2024. He said the company is in the first two years of its launch phase in the U.S., anchored by the IMerge dataset in lower-risk MDS.

Semerjian said Geron reported $184 million of net revenue in 2025 and reiterated company guidance for $220 million to $240 million of net revenue in 2026. He attributed the company’s confidence in its outlook to a streamlined operating approach and what he characterized as a sharper focus on commercial activities that “move the needle,” including digital and non-personal promotion, regional meetings, and targeting high-volume accounts.

Semerjian also emphasized Geron’s balance sheet, stating the company has “$400 million on our balance sheet.”

Where RYTELO fits in lower-risk MDS treatment Chief Medical Officer Joseph Eid, EVP and CMO, framed MDS as a “spectrum of disease,” describing high-risk MDS as being “very close to acute myelogenous leukemia” and noting that MDS is “a precursor to leukemic transformation.”

Eid reviewed a treatment landscape that has evolved from transfusion support to broader use of ESAs, luspatercept, and other therapies, including lenalidomide for 5q deletion and hypomethylating agents (HMAs) such as azacitidine and decitabine. He said the paradigm has shifted toward ESAs or luspatercept in first line, with luspatercept “making a move into capturing more of that first line.”

He added that “depending on whether it’s ESAs or luspatercept, the second line preferentially is now imetelstat,” citing NCCN guideline positioning that, in his description, pushes HMAs into “third line and beyond.” Eid also said imetelstat has applicability in first line within the label for patients who are ESA-ineligible, including those with EPO levels over 500 and high transfusion burden.

Physician experience: cytopenias, education, and line of therapy Both executives said U.S. adoption has required significant education, in part because Semerjian stated that about 90% of patients in the pivotal IMerge trial were enrolled outside the U.S. Semerjian said Geron has been working to build awareness among U.S. hematologists about mechanism of action, durable response, and how to manage cytopenias.

Eid discussed data presented at ASH related to cytopenias, describing them as a predictable early treatment effect. He said cytopenias tend to occur within the first two to three cycles with “predictable recovery within two to four weeks in over 80% of patients” with lower levels of cytopenia. Eid said the company’s interpretation is that cytopenias are tied to the drug’s on-target activity against mutated MDS clones, and that patients with cytopenias “tend to be the ones that have the most durable, robust response.”

In discussing real-world management, Eid said that earlier in the launch, some patients were taken off imetelstat due to lack of physician familiarity with cytopenias. He said the company now emphasizes education and an analogy to lenalidomide in 5q deletion MDS, where cytopenias have also been correlated with response. Eid also said that in IMerge, the incidence of bleeding or infection on placebo was similar to that seen on imetelstat, which he described as minimal.

On treatment burden, Eid said that when growth factor support is used, it is typically “no more than one injection,” and he contrasted imetelstat’s effects with chemotherapy, saying imetelstat targets “the bad clones” rather than indiscriminately affecting all marrow cells.

Semerjian addressed the line-of-therapy mix, saying Geron disclosed in its full-year 2025 results that it believes 30% of business is coming from first-line and second-line patients, with 70% coming from third-line-plus. He characterized that later-line skew as common in early launches and said the company is focused on moving adoption toward the approved second-line setting, which he estimated at about 8,000 patients in the U.S.

Frontline sequencing and RS-negative dynamics Eid discussed ring sideroblast (RS) status and physician decision-making, pointing to luspatercept performance differences in RS-negative patients as a factor in how clinicians may evaluate treatment options. He said physicians increasingly view imetelstat as a drug that can work across RS-positive and RS-negative settings and across mutation and transfusion-burden profiles, describing imetelstat as “more of a disease modifying agent.”

He also addressed sequencing between ESAs and luspatercept, describing ESAs as stimulating progenitors while luspatercept acts as an erythroid maturation agent. Eid said luspatercept has stronger comparative data versus ESAs in the same population, and he described ESAs as “not as effective post-luspatercept.” Semerjian said the shift of luspatercept into frontline use could create “tailwinds” for RYTELO in second line as patients still need additional options after frontline therapy.

Ex-U.S. commercialization and the Phase 3 myelofibrosis program Semerjian said imetelstat is a wholly owned asset with worldwide rights and that Geron has EMA approval “as of last year,” but has not fully commercialized in Europe. He said the company is evaluating paths forward, including potential partnerships, and emphasized the importance of pricing strategy and “gated” decision-making. He also noted that many European centers enrolled imetelstat trial patients, creating what he described as a stronger base of familiarity among European physicians.

On the MF program, Eid described the ongoing IMpactMF Phase 3 trial as a 2:1 randomization of imetelstat versus best available therapy, with overall survival as the primary endpoint. He said the trial design was supported by Phase 2 EMBARK data, a randomized study of two imetelstat doses that showed benefit in symptom relief and overall survival, with the higher dose given every three weeks. Eid said the company expects to reach an interim analysis in the second half of the year, driven by death events, and suggested the Data Monitoring Committee will likely recommend continuing to the final analysis given the interim’s high statistical bar.

Eid also said that while the MF standard of care has expanded from one to multiple JAK inhibitors, he does not see evidence that any particular JAK inhibitor has improved survival, characterizing them instead as symptom-relief therapies. He said the IMpactMF study has taken longer partly because patients are living longer on trial, reflecting broader improvements in cancer supportive care.

About Geron (NASDAQ:GERN) Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.

See Also Five stocks we like better than Geron

April 22, 2026 07:00 ET  | Source: Geron Corporation

FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its first quarter 2026 financial results and business highlights before the market opens on Wednesday, May 6, 2026 via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.

A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company’s website at www.geron.com.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]

Achieved $51.8 million in RYTELO® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025

Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively

Strengthened leadership team with appointments of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary and Patricia S. Andrews and Constantine Chinoporos to Board of Directors

Ended Q1 2026 with cash, cash equivalents, restricted cash and marketable securities of $341 million

Company to host conference call and webcast today, May 6, 2026, at 8:00 a.m. ET

FOSTER CITY, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the first quarter of 2026 and recent business highlights.

“We are encouraged by RYTELO demand and net revenue growth in the first quarter. Our refocused commercial strategy, energized team, and commitment to execute with excellence position us well to continue building on these results,” said Harout Semerjian, President and Chief Executive Officer of Geron. “We also made progress on our potential European lower-risk MDS commercial strategy for RYTELO, with the goal of maximizing its value while preserving pricing integrity in the U.S. We plan to provide an update on our European commercial plans by the end of the year. Our 2026 priorities remain focused on growing RYTELO net revenue in the U.S., pursuing pathways to bring RYTELO to patients outside of the U.S., advancing our Phase 3 IMpactMF trial, remaining financially disciplined, and evaluating opportunistic innovation, as we work towards building a leading hematology company.”

Recent Business Highlights

Reported RYTELO net product revenue of $51.8 million in the first quarter of 2026. Grew RYTELO demand by 6% in the first quarter 2026, compared to the fourth quarter 2025. Increased ordering accounts by roughly 12% in the first quarter 2026 to approximately 1,450.   Achieved inclusion of imetelstat to the National Comprehensive Cancer Network® (NCCN®) Chemotherapy Order Templates, positioning imetelstat as an active therapeutic for lower-risk myelodysplastic syndromes/neoplasms (LR-MDS).Advanced investigator-sponsored and real-world evidence trials focusing on RYTELO’s mechanistic studies, combinations and sequencing, earlier-line use and new settings. Initial data is expected in the second half of 2026.Published a manuscript in Blood Cancer Journal titled “Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes” that expands on the 2025 American Society of Hematology oral presentation of pooled analysis from the IMerge population that suggests treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independence in LR-MDS.Published a manuscript in Blood Neoplasia titled “Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial” that found using time without transfusion reliance (TWiTR) as a novel method for evaluating health-related quality of life (HR-QOL) demonstrated the impact imetelstat has on the overall health and wellbeing of patients with LR-MDS in the IMerge study.Continued to invest in Chemistry, Manufacturing and Controls to strengthen RYTELO’s supply chain with the validation of a second supplier.Strengthened the leadership team with the appointments of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary and Patricia S. Andrews and Constantine Chinoporos to Geron’s Board of Directors. First Quarter 2026 Financial Results

Cash and Marketable Securities

As of March 31, 2026, Geron had approximately $341.0 million in cash, cash equivalents, restricted cash and marketable securities, compared to $401.1 million as of December 31, 2025, which provides the Company with cash for the foreseeable future.

Net Loss

For the three months ended March 31, 2026, the Company reported a net loss of $3.6 million, or $0.01 per share, compared to $19.8 million, or $0.03 per share, for the three months ended March 31, 2025. The decrease in net loss is directly attributable to an increase in RYTELO net product revenue for the quarter and a decrease in operating expenses.

Revenues

Total product revenue, net for the three months ended March 31, 2026, was $51.8 million, compared to $39.4 million for the three months ended March 31, 2025.

Total revenues for the three months ended March 31, 2026 was $51.8 million, compared to $39.6 million for the three months ended March 31, 2025.

Costs and Operating Expenses

Total costs and operating expenses for the three months ended March 31, 2026, were $51.7 million, compared to $56.3 million for the three months ended March 31, 2025. The decrease is primarily due to a decrease in personnel related expenses resulting from the reduction in force in 2025.

Cost of goods sold was approximately $1.7 million for the three months ended March 31, 2026, compared to $1.2 million for the three months ended March 31, 2025, which consisted of costs to manufacture and distribute RYTELO.

Research and development expenses for the three months ended March 31, 2026, were $15.0 million, compared to $15.1 million for the same period in 2025. The decrease in research and development expenses was a result of lower headcount costs from the workforce reduction in December 2025 and were partially offset by increases in clinical trial costs.

Selling, general and administrative expenses for the three months ended March 31, 2026, were $35.4 million, compared to $40.0 million for the same period in 2025. The decrease in selling, general, and administrative expenses was primarily due to lower general and administrative personnel-related expenses as a result of the workforce reduction in December 2025.

2026 Financial Guidance

For fiscal year 2026, the Company expects RYTELO net product revenue to be in the range of $220 million to $240 million. Geron also expects total operating expenses to be between $230 million and $240 million. Total operating expenses include non-cash items such as stock-based compensation expense, amortization of debt discounts and issuance costs, and depreciation and amortization.

Based on current operating plans and assumptions, the Company believes that its existing cash, cash equivalents, restricted cash and marketable securities, together with anticipated net revenues from U.S. sales of RYTELO, will be sufficient to fund projected operating requirements for the foreseeable future.

Conference Call

Geron will host a conference call at 8:00 a.m. ET on Wednesday, May 6, 2026, to discuss business updates and first quarter 2026 financial results.

A live webcast of the conference call will be available on the “Investors & Media” page of the Company’s website at www.geron.com. A replay of the webcast will be archived and available on the Company's website.

About RYTELO (imetelstat)
RYTELO (imetelstat) is an oligonucleotide telomerase inhibitor approved in the U.S. for the treatment of adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). It is indicated to be administered as an intravenous infusion over two hours every four weeks.

In addition, RYTELO is approved in the European Union as a monotherapy for the treatment of adult patients with transfusion-dependent anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.

RYTELO is a first-in-class treatment that works by inhibiting telomerase enzymatic activity. Telomeres are protective caps at the end of chromosomes that naturally shorten each time a cell divides. In LR-MDS, abnormal bone marrow cells often express the enzyme telomerase, which rebuilds those telomeres, allowing for uncontrolled cell division. Developed and exclusively owned by Geron, RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration and the European Commission.

Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide, available at https://pi.geron.com/products/US/pi/rytelo_pi.pdf.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. To learn more, visit www.geron.com or follow us on LinkedIn.

Use of Forward-Looking Statements
Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, include, without limitation, those regarding: (i) Geron’s 2026 financial guidance, including its expected full year 2026 RYTELO net product revenue range and total operating expense range; (ii) Geron being positioned to build in the future on RYTELO demand and net revenue growth in the first quarter of 2026; (iii) Geron’s potential European lower-risk MDS commercial strategy for RYTELO; (iv) Geron’s 2026 priorities, including remaining focused on growing RYTELO net revenue in the U.S., pursuing pathways to bring RYTELO to patients outside of the U.S., advancing its Phase 3 IMpactMF trial, remaining financially disciplined, and evaluating opportunistic innovation; (v) the expected timing of initial data from investigator-sponsored and real-world evidence trials focusing on RYTELO’s mechanistic studies, combinations and sequencing, earlier-line use and new settings; (vi) the pooled analysis from the IMerge population that suggests treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independence in LR-MDS; (vii) Geron’s belief that its existing cash, cash equivalents, restricted cash and marketable securities, together with anticipated net revenues from U.S. sales of RYTELO, will be sufficient to fund projected operating requirements for the foreseeable future; and (viii) and other statements that are not historical facts, constitute forward-looking statements. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (a) whether Geron is successful in commercializing RYTELO for the treatment of certain patients with lower-risk MDS with transfusion dependent anemia and achieves market acceptance across the breadth of the eligible patient segments in RYTELO’s approved indication; (b) whether the FDA and European Commission will approve imetelstat for other indications with labeling claims that are necessary or desirable for the successful commercialization of RYTELO and without significant labeling restrictions or requirements in an approved label; (c) Geron’s plans to commercialize RYTELO outside of the U.S., including Geron’s lack of experience selling, marketing and commercializing an approved drug outside of the U.S., and risks related to operating outside of the U.S.; (d) Geron’s future opportunities and plans, including the uncertainty of future revenues, expenses and other financial performance and results, and the related risk Geron may be unable to meet its 2026 financial guidance; (e) whether Geron overcomes potential delays and other adverse impacts that may be caused by enrollment, clinical, safety, efficacy, technical, scientific, intellectual property, manufacturing, supply chain, pricing, coverage and reimbursement, market penetration, regulatory and healthcare challenges in order to obtain and maintain the financial resources for and meet expected timelines and planned milestones; (f) whether regulatory authorities permit the further development of imetelstat on a timely basis, or at all, without any clinical holds; (g) whether any future safety or efficacy results of RYTELO treatment cause its benefit-risk profile to become unacceptable; (h) whether imetelstat actually demonstrates disease-modifying activity in patients, including transfusion independence in LR-MDS, and the ability to target the malignant stem and progenitor cells of the underlying disease; (i) whether Geron meets its post-marketing requirements and commitments for RYTELO; (j) whether there are failures or delays in manufacturing or supplying sufficient quantities of RYTELO (imetelstat) or other clinical trial materials that negatively impact commercialization of RYTELO or the conduct and timing of clinical trials; (k) that the expected timing for initial data from investigator-sponsored and real-world evidence trials may be delayed, perhaps significantly; (l) that the projected timing for the interim and final analyses of the Phase 3 IMpactMF trial may prove to be incorrect and may be delayed, perhaps significantly, depending on actual death rates in the trial which are beyond Geron’s control; (m) whether Geron stays in compliance with and satisfies its obligations under its debt and synthetic royalty financing agreements; (n) whether Geron successfully manages the changes in its workforce and realizes expected operating expense savings resulting from its completed strategic restructuring plan; and (o) as it relates to Geron’s belief as to the sufficiency of its cash resources, if Geron does not generate net revenues from commercial sales of RYTELO at the levels it anticipates, if it experiences unforeseen events or chooses to make other investments in its business, or if its assumptions regarding its projected operating expenses are otherwise incorrect, Geron may require additional funding, which may not be available to Geron on commercially-reasonable terms or at all. Additional information on the above risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron’s filings and periodic reports filed with the Securities and Exchange Commission under the heading “Risk Factors” and elsewhere in such filings and reports, including Geron’s annual report on Form 10-K for the year ended December 31, 2025, and subsequent filings and reports by Geron, including its upcoming quarterly report on Form 10-Q for the quarter ended March 31, 2026. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances.

 GERON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
  Three Months Ended March 31(In thousands, except per share data) 2026   2025  (Unaudited) (Unaudited)Revenues:   Product revenue, net 51,771   39,436 Royalties 66   167   51,837   39,603 Costs and operating expenses:   Cost of goods sold 1,692   1,206 Research and development 14,956   15,078 Selling, general and administrative 35,425   40,023 Restructuring charges (394)  — Total costs and operating expenses 51,679   56,307 Loss from operations 158   (16,704)Interest income 3,421   5,152 Interest expense (7,147)  (8,200)Other income and (expense), net (74)  (83)Net loss$(3,642) $(19,835)Basic and diluted net loss per share:   Net loss per share$(0.01) $(0.03)Shares used in computing net loss per share 669,375   665,905   GERON CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
 (In thousands)March 31,
2026 December 31,
2025 (Unaudited) (Note 1)Current assets:   Cash, cash equivalents and restricted cash$70,779 $79,440Current marketable securities 243,506  280,359Other current assets 184,246  160,472Total current assets 498,531  520,271    Noncurrent marketable securities 26,686  41,289Property and equipment, net 1,000  884Deposits and other assets 7,903  8,096 $534,120 $570,540    Current liabilities$73,570 $111,542Noncurrent liabilities 231,442  233,126Stockholders’ equity 229,108  225,872 $534,120 $570,540  Note 1: Derived from audited financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2025.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]

Geron Corporation (GERN) Q1 2026 Earnings Call Transcript

Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

A downtrend has been apparent in Geron (GERN - Free Report) lately with too much selling pressure. The stock has declined 21.2% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.

We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.

RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.

Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.

So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefiting from the inevitable rebound.

However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.

Why GERN Could Bounce Back Before LongThe RSI reading of 28.87 for GERN is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.

This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering GERN in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 57.9% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.

Moreover, GERN currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

June 01, 2026 08:00 ET  | Source: Geron Corporation

FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET in Miami, FL.

A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron’s website at www.geron.com.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]

Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript